[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abdominal-aortic-aneurysms-aaa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abdominal-aortic-aneurysms-aaa":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100651022","a-clinical-investigational-study-of-ankuratm-ii-aaa-ie-and-ae-stent-graft-system-for-endovascular-treatment-of-abdominal-aortic-aneurysm-100651022",false,"NCT07754240","A Clinical Investigational Study of Ankura™ II AAA, IE and AE Stent Graft System for Endovascular Treatment of Abdominal Aortic Aneurysm","Inclusion Criteria:\n\n1. 18 years ≤ age ≤80years, no gender limitation.\n2. Patients diagnosed with infrarenal abdominal aortic aneurysm and should meet at least one of the following conditions:\n\n   1. The maximum diameter of abdominal aortic aneurysm is 55 mm or more in male patients or 50 mm or more in female patients;\n   2. The maximum diameter of abdominal aortic aneurysm has increased by more than 5 mm in the last 6 months or 10 mm in the last 1 year;\n   3. Abdominal aortic aneurysm oppresses important organs and viscera and causes symptoms (such as abdominal pain, lower back pain, etc.).\n3. Anatomical criteria:\n\n   * Diameter of the proximal abdominal aortic aneurysm neck ranges from 17 mm to 33 mm;\n   * Length of the proximal abdominal aortic aneurysm neck ≥ 10 mm;\n   * Angle of the proximal abdominal aortic aneurysm neck ≤ 75 degrees;\n   * At least one side of the iliac artery anchorage zone has a diameter of 20 to 25 mm, while the other side of the iliac artery anchorage zone could be 7 to 25 mm；\n   * Length of the bilateral iliac artery anchorage zone ≥ 15mm;\n   * Adequate iliac or femoral vessel access\n4. Patients who are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent form, and are willing to complete the follow-up visits as per the protocol.\n\nExclusion Criteria:\n\n1. Patients with ruptured or leaking abdominal aortic aneurysm;\n2. Patients with infectious abdominal aortic aneurysm;\n3. Patients with abdominal aortic dissection;\n4. Patients with traumatic aortic disease;\n5. Patients with severe stenosis, calcification or mural thrombus in the stent anchoring zone likely to cause difficult covered stent apposition or the impact on stent patency;\n6. Patients with mesenteric blood flow mainly supplied by the inferior mesenteric artery;\n7. Patients with accessory renal artery original from abdominal artery;\n8. Patients who have undergone abdominal aortic surgery or endovascular intervention;\n9. Patients with stroke (Except for TIA), myocardial infarction or unstable angina within 3 months; The unstable angina is characterized by: progressively increased angina symptoms, new onset of angina while resting or during the night, or prolonged angina duration\n10. Patients with allergies to contrast agents, stent graft and delivery system materials (i.e., nitinol, polyester, PTFE, nylon polymer materials);\n11. Patients with allergies or contraindications to anticoagulant and antiplatelet drugs；\n12. Patients with abnormal hepatic and renal functions before operation (ALT or AST exceeding five times the upper limit of normal; STB exceeding two times the upper limit of normal; baseline serum creatinine exceeding 2.0 mg\u002FdL (approximately 176.8 μmol\u002FL));\n13. Patients who have undergone major surgery within 30 days prior to the procedure, or who are scheduled to undergo major surgery within 30 days following the procedure;\n14. Patients have morbid obesity (BMI of \\>40.0 kg\u002Fm2) or other clinical conditions that inhibit visualization of the aorta;\n15. Patients with systemic or localized infection likely to increase the risk of endovascular graft infection;\n16. Patients with connective tissue diseases related to the aorta, such as Marfan's syndrome;\n17. Patients with life expectancy of less than 1 year;\n18. Female patients who are in pregnancy or lactation, or plan to become pregnant;\n19. Patients who are not suitable for endovascular treatment according to the investigator's judgement;\n20. Patients who are participating in other device or drug clinical investigational studies.","ALL","18 Years","80 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this clinical investigational study is to evaluate the safety and efficacy of the Ankura™ II AAA, AE Stent Graft System and the large-size Ankura™ II IE Stent Graft System (i.e., IE stent grafts with distal diameters of 24, 26, and 28 mm) for endovascular treatment of abdominal aortic aneurysm in patients with infrarenal abdominal aortic aneurysm who are suitable for endovascular intervention.\n\nThe primary safety endpoint is the incidence of major adverse events within 30 days after the procedure. The primary efficacy endpoint is the 12-month treatment success rate.",[26],"Abdominal Aortic Aneurysms (AAA)",[26,28,29],"Lifetech Scientific","Ankura II Abdominal Aortic Stent Graft System","RECRUITING","2026-08-17",{"date":33,"type":34},"2026-08-18","ACTUAL",{"date":36,"type":20},"2026-09-30",{"date":38,"type":20},"2033-06-30",{"name":40,"class":41},"Lifetech Scientific (Shenzhen) Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100595009","endovascular-repair-with-fenestrated-treo-stent-graft-system-in-aaa-100595009","NCT07026877","Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA","A Prospective, Multicenter, Non-Blinded, Non-Randomized Pivotal Study of the Fenestrated TREO Stent-Graft System in Subjects With Abdominal Aortic Aneurysms Requiring a Fenestrated Graft and Suitable for Endovascular Repair","Inclusion Criteria:\n\n* 18 years or older at the time of consent\n* Life expectancy is greater than 2 years\n* An abdominal aortic or aorto-iliac aneurysm requiring a fenestrated graft and with morphology suitable for endovascular repair (confirmed by Computed Tomography (CT) with contrast performed within 6 months of planned implant procedure) as follows:\n\n  1. Maximum aneurysm diameter of ≥5.5 cm for male ( ≥5.0 cm for female) or\n  2. Maximum AAA diameter exceeding two times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements (or saccular aneurysm that warrants treatment in the opinion of the investigator) or\n  3. Aneurysm with a history of growth \\> 0.5 cm in 6 months and\n  4. Minimum 0 mm of healthy aorta\\* below the most inferior renal artery that the physician plans on preserving and no renal artery involvement (juxtarenal aneurysms) or\n  5. At least one renal artery involved in the aneurysm and minimum 2 mm below the celiac (suprarenal aneurysms) \\*Healthy aorta is defined as segment of aorta with parallel aortic wall with minimal (\\\u003C10%) or no difference in diameter and minimal atherosclerotic debris, thrombus, or calcification.\n* Proximal landing zone:\n\n  1. ≥20 mm length\n  2. 20-32 mm diameter\n  3. ≤60° angle relative to the axis of the suprarenal aorta\n  4. ≤60° angle relative to the long axis of the aneurysm\n* Distal (iliac) landing zone with:\n\n  1. 8-13 mm inside diameter\u002F ≥10 mm length\n  2. \\>13-20 mm inside diameter\u002F ≥15 mm length\n* Distal aortic diameter (above the iliac bifurcation) ≥70% of the sum of the iliac limb graft diameters\n* Minimum 18 mm aortic lumen diameter at the level of the fenestrations\n* Pathology that requires maximum 5 fenestrations in the main body\n* Pathology that requires fenestration a minimum 3 mm apart (edge to edge)\n* Branch vessels (to be bridged to the fenestrated graft) with:\n\n  1. 5-9 mm diameters\n  2. ≥13 mm distal landing zone (or ≥15 mm if there is a gap between fenestration and target vessel)\n* Adequate renal function to tolerate contrast-enhanced CTA\n* Adequate vascular access compatible with required delivery systems\n* Willingness to comply with the follow-up evaluation schedule documented in a signed informed consent prior to implant\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Existing endovascular graft in the treated segment intended to be repaired with the Fenestrated TREO Stent-Graft System\n* Dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)\n* Implant procedure as planned does not allow for at least one patent hypogastric artery left intact, unless both are occluded on pre-op imaging.\n* A branch vessel(s) that is dissected or has significant calcification, tortuosity, thrombus formation that would interfere with bridging stent delivery or sealing (as determined by treating physician)\n* Severe untreated coronary artery disease and\u002For unstable angina, significant areas of myocardium at risk (based on coronary angiogram or radionuclide scans), left ventricular ejection fraction \\\u003C20%, or recent diagnosis of congestive heart failure (CHF; as determined by treating physician).\n* Stroke or myocardial infarction within 6 months of the planned treatment date\n* Chronic obstructive pulmonary disease requiring routine need for oxygen therapy outside the hospital setting (e.g., daily or nightly home use)\n* Chronic Kidney Disease (CKD) stage ≥3b.\\*\n\n  \\* During Stage 2, patients with severe CKD (stage ≥3b) can be included in the Expanded Access Arm if otherwise eligible.\n* Active systemic infection or is suspected of having an active systemic infection (e.g., acquired immune deficiency syndrome (AIDS)\u002Fhuman immunodeficiency virus (HIV), sepsis)\n* Clinical conditions that would severely compromise or impair x-ray visualization of the aorta (as determined by treating physician).\n* History of an aortopathic connective tissue disease (e.g., Marfan's syndrome)\n* Mycotic aneurysm\n* Significant or circumferential calcification or mural thrombus (as determined by treating physician):\n\n  1. in the proximal aortic neck\n  2. in the distal iliac landing zone\n  3. within the treatment length, which may adversely impact device patency\n* Cannot receive intraprocedural anticoagulation per the investigator's standard of care, or antiplatelet therapy post-procedurally as per the investigator's standard of care.\n* Blood coagulation disorder or bleeding diathesis, the treatment for which cannot be suspended pre- and post-repair\n* An investigational study drug or biologic within 30 days of planned procedure or an investigational device within one year of planned procedure or any other treatment that may interfere with the interpretation of the study results.\n* Medical, social or psychological issues that the investigator believes may interfere with study treatment or follow-up.\n* Untreatable allergy or sensitivity to contrast media, nitinol\u002Fnickel, Tantalum, Platinum Iridium (PtIr), 316 stainless steel, ePTFE (expanded polytetrafluoroethylene), PTFE (polytetrafluoroethylene) Impregnated polyester fiber, or polyester\n* Other major surgical or medical intervention within 45 days of the planned procedure or plan to undergo other major surgical or medical intervention within 45 days post implantation (e.g., coronary artery bypass graft (CABG), organ transplantation, renal stenting)",{"count":51,"type":20},20,[23],"The goal of this clinical trial is to learn if the Fenestrated TREO Stent-Graft System works to treat abdominal aneurysms in adults. An abdominal aneurysm is a bulge in the main blood vessel (the aorta) which carries blood from the heart, through the chest and abdomen. It will also learn about the safety of Fenestrated TREO Stent-Graft System.\n\nThe main question it aims to answer is: Can the the Fenestrated TREO Stent-Graft System be used to treat participants with a specific type of abdominal aneurysm called a juxtarenal abdominal aortic aneurysm?\n\nParticipants will: Have the the Fenestrated TREO Stent-Graft System implanted via an endovascular surgical procedure and visit the hospital for a follow up period of 5 years, for checkups, tests and imaging scans.",[26],[56,57,58],"Abdominal Aortic Aneurysm","juxtarenal","endovascular","2026-02-16",{"date":61,"type":34},"2026-02-18",{"date":63,"type":34},"2025-11-18",{"date":65,"type":20},"2030-05-29",{"name":67,"class":41},"Bolton Medical",7,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100584058","use-of-artificial-intelligence-to-predict-complications-following-abdominal-aortic-surgery-100584058","NCT06884397","Use of Artificial Intelligence to Predict Complications Following Abdominal Aortic Surgery","Implantation of an Endovascular Prosthesis for the Treatment of Abdominal Aortic Aneurysms: Use of a Machine Learning Model From CT Images to Predict Complications","AORTAPREDICT","Inclusion Criteria:\n\n* Treated for an abdominal aortic aneurysm through endovascular prosthesis implantation\n\nExclusion Criteria:\n\n* Underwent intraoperative embolization of the inferior mesenteric artery or aneurysmal sac\n* Refuse the use of their data",{"count":78,"type":20},300,"OBSERVATIONAL","Abdominal aortic aneurysm, a condition characterised by an increase in the diameter of the aorta, can be treated either surgically or endovascularly. In the latter, an endoprosthesis consisting of a metal spring covered with an impermeable fabric is inserted through an artery and deployed inside the aorta. This new method appears to be less invasive than surgery, but its long-term results are not yet fully understood. As a result, patients who have undergone this treatment are monitored by their surgeon to ensure that there is no endoleak. Several research teams have proposed analysing medical images to predict this risk of endoleak. Doctors are now trying to use artificial intelligence to automate the analysis of these images.",[26],[83,84,85,86,87],"Aortic Aneurysm, Abdominal","Prostheses and Implants","Endoleak","Angiography, Computed Tomography","machine learning algorithm","2025-06-17",{"date":90,"type":34},"2025-06-18",{"date":92,"type":34},"2025-04-14",{"date":94,"type":20},"2026-06-30",{"name":96,"class":97},"Groupe Hospitalier de la Rochelle Ré Aunis","OTHER"]